Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
With
Roche Pharma AG
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, ≥ 18 years of age
Active rheumatoid arthritis
Inadequate treatment with any DMARD other than methotrexate
You may not be if
Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis
Concurrent treatment with any DMARD other than methotrexate
Previous treatment with any cell-depleting therapies
Any surgical procedure in past 12 weeks, or planned within 48 weeks after baseline
Clareo Health | A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
